


In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claims 1, 3, 10, 12-19, and 21-23 without prejudice to their presentation in another application, and amend claims 2, 4, 5, and 7 as follows:

- (canceled).
- (currently amended) A compound according to Claim 1, in accord with formula II:



II

wherein:

R^1 , R^2 , R^3 , R^4 , R^5 , and R^7 are as defined in Claim 1,

R^1 and R^2 are, independently, selected from hydrogen, CN, CF_3 , OCF_3 , OCF_2 , halogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, R^a , R^b , SR^a , NR^aR^b , $CH_2NR^aR^b$, OR^c , or CH_2OR^c , wherein R^a , R^b , and R^c are independently at each occurrence selected from hydrogen, C_{1-6} alkyl, $C(O)R^d$, $C(O)NHR^d$, CO_2R^d , or R^a and R^b may together be $(CH_2)_jG(CH_2)_k$ or $G(CH_2)_kG$ wherein G is oxygen, j is 1, 2, 3, or 4, k is 0, 1, or 2; R^d at each occurrence is independently selected from C_{1-6} alkyl;

R^3 is hydrogen or C_{1-4} alkyl;

R^4 and R^5 are, independently, selected from halogen, C_{1-4} alkoxy or halogenated C_{1-4} alkyl; and

R⁷ is hydrogen or C₁₋₄alkyl;

or a pharmaceutically acceptable salt thereof.

3. (canceled).

4. (currently amended) A compound according to ~~Claim 1~~ Claim 2, wherein:

R¹ is selected from hydrogen, methoxy or ethyl;

R² is selected from hydrogen or methoxy;

R³ is selected from hydrogen or methyl;

or a pharmaceutically acceptable salt thereof.

5. (currently amended) A pharmaceutically-acceptable salt of a compound according to ~~Claim 1~~ Claim 2 made with an inorganic or organic acid which affords a physiologically-acceptable anion.

6. (previously presented) A pharmaceutically-acceptable salt of a compound according to Claim 5, wherein said inorganic or organic acid is selected from hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, sulfamic, para-toluenesulfonic, acetic, citric, lactic, tartaric, malonic, fumaric, ethanesulfonic, benzenesulfonic, cyclohexylsulfamic, salicylic or quinic acids.

7. (currently amended) A pharmaceutical composition comprising a compound according to ~~Claim 1~~ Claim 2, and a pharmaceutically-acceptable carrier.

8-19. (canceled).

20. (previously presented) A compound according to Claim 1, wherein said compound is selected from:

1-N-Methyl-4-(4-chlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-methoxyphenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(2-N-methyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-chlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(2-N-methyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(2-N-ethyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(2-N-ethyl-2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(2,4-dimethoxy-3-cyanonaphth-1-yl)-(2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(2-N-methyl-2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(2-N-methyl-2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(2-N-methyl-2-azaprop-1-yl))piperidine; and

4-(4-Fluorophenyl)-4-(3-(2,4-dimethoxy-3-cyanonaphth-1-yl)-(2-N-methyl-2-azaprop-1-yl))piperidine.

21-23. (canceled).